Previous 10 | Next 10 |
Ayala Pharmaceuticals (NASDAQ:AYLA): Q3 GAAP EPS of -$0.68 beats by $0.12. Revenue of $0.63M (-4.5% Y/Y) misses by $0.21M. Press Release For further details see: Ayala Pharmaceuticals EPS beats by $0.12, misses on revenue
- Presented Preliminary Clinical Data from 6mg Cohort of Phase 2 ACCURACY Trial of AL101 in R/M ACC Demonstrating 70% Disease Control Rate at ESMO 2021 – - Presented Pre-Clinical Proof of Concept Data for Enhanced Activity of AL101 in Combination with Approved Cancer Therap...
REHOVOT, Israel and WILMINGTON, Del., Nov. 10, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announce...
REHOVOT, Israel and WILMINGTON, Del., Sept. 23, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announc...
- Posters presented at the European Society for Medical Oncology (ESMO) Virtual Congress 2021 - Preliminary data showed meaningful clinical activity of AL101 6mg monotherapy with 70% disease control rate - AL101 was well tolerated with manageable side effects REHOV...
AL101 Data Expected Shortly. Ayala plans to present data from AL101 at the European Society for Medical Oncology (ESMO) Virtual Congress 2021, to be held September 16-September 21, 2021. The first presentation is from the Phase 2 ACCURACY clinical trial testing AL101 in recurrent/metastatic (R...
REHOVOT, Israel and WILMINGTON, Del., Sept. 01, 2021 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (NASDAQ: AYLA), a clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, today announc...
- Enrolled the First Patient in the Phase 2/3 Pivotal Trial of AL102 for the Treatment of Desmoid Tumors - Multiple Near-Term Milestones Across Clinical-Stage Pipeline - Updated ACCURACY Trial Data to Be Presented at ESMO 2021- REHOVOT, Israel and WILMINGTON, ...
Drug-resistant superbugs have threatened human health for decades. The situation is getting worse because of the shortage of new antibiotics. But what if we changed the way we aim to treat them, and trained our cells to kill these invaders instead of relying on antibiotics to do the dirty work...
Artystarty/iStock via Getty Images Thanks to the prospects of earning a spot in the S&P 500 Index, Moderna (MRNA) jumped ~23.0% this week to breeze past $100B market capitalization. The frontrunner in COVID-19 vaccine development has taken less than three yea...
News, Short Squeeze, Breakout and More Instantly...
Ayala Pharmaceuticals Inc. Company Name:
AYLA Stock Symbol:
NASDAQ Market:
Successful End-of-Phase 2 meeting with FDA regarding AL102 for the treatment of desmoid tumors Enrollment in the Phase 3 segment of RINGSIDE trial evaluating AL102 continuing globally as planned Definitive merger agreement with Biosight, expected to close near end of Q3 2023 REHOVOT...
REHOVOT, Israel and MONMOUTH JUNCTION, N.J., Aug. 01, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmaceuticals, Inc. (OTCQX: ADXS), a publicly-traded clinical-stage oncology company, today announced that it will present posters on its gamma secretase inhibitors AL102 and AL101 at the European Societ...
Company confirms FDA agreement on key elements of the Phase 3 segment of ongoing RINGSIDE study, including dosing regimen of 1.2mg once daily Enrollment in Phase 3 continuing as planned REHOVOT, Israel & MONMOUTH JUNCTION, N.J., July 05, 2023 (GLOBE NEWSWIRE) -- Ayala Pharmace...